Tuesday, 15 Oct 2019

You are here

Ten Contemporary Challenges Facing Lupus Treatment

A group of French researchers have pooled their interests to identify the challenges ahead in the management of patients with systemic lupus erythematosus (SLE). 

This introspective review puts forth the authors’ perceptions of the 10 most important contemporary challenges in the management of SLE. The paper represents the roundtable consensus of a multidisciplinary team of clinicians, pharmacists and researchers from a national centre for rare autoimmune and systemic diseases (Strasbourg, France).

The 10 main contemporary challenges in SLE include: 

  • T2T: favouring disease remission (or low disease activity).
  • Limiting the use of glucocorticoids.
  • Deriving more comprehensive tools for the evaluation of disease activity.
  • Developing more effective (and better tolerated) drugs (and more successful trials).
  • Dissecting the heterogeneity of the disease at the molecular and genetic levels.
  • Identifying relevant biomarkers for individualised treatment.
  • Managing fertility and pregnancy.
  • Managing comorbidities(e.g., cardiovascular risk, infections, osteoporosis).
  • Improving the network of care (the patients’ perspective).
  • Favouring a holistic approach (integrating fatigue, adherence to treatment, physical activity).

These 10 contemporary challenges in SLE may be considered as a roadmap for those involved in the daily care of patients with SLE, as well as for researchers who may wish to contribute to an improved management of this rare and complex disease.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Declining Trends in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis Mortality in the USA

Annals of Internal Medicine reports that age-adjusted mortality rates for antineutrophil cytoplasmic autoantibody–associated vasculitides (AAV) have improved over time - with a decline of nearly 2 percent per year in the United States from 1999 to 2017. Nevertheless, long-term outcomes continue to lag behind mortality rates of the general population.

Serum Interferon Predicts Lupus Flares

Elevated serum levels of interferon-α among patients whose systemic lupus erythematosus (SLE) was in remission helped predict future disease flares, European researchers found.

Among 254 SLE patients who were in remission, 26% had abnormally high serum levels of interferon-α at baseline, according to Alexis Mathian, MD, of Pitié-Salpêtrière Hospital in Paris, and colleagues.

ILD Patients At Risk for Autoimmune Disease

Patients diagnosed with interstitial pneumonia with autoimmune features (IPAF) are at an increased risk of developing a systemic autoimmune rheumatic disease (ARD).

A retrospective study of interstitial lung disease (ILD) patients from the Columbia University Irving Medical Center (2009 to 2017) looked for those who did or did not meet IPAF criteria.

MMWR: Increased Opioid Use in Lupus

Opioids are generally not indicated for pain in systemic lupus erythematosus (SLE) and other rheumatic diseases because of limited efficacy and risks for preference and adverse health effects.

Low Dose IL-2 Effective in Lupus

A double-blind, placebo-controlled clinical trial of low-dose IL-2 in patients with systemic lupus erythematosus (SLE) has shown that low-dose IL-2 induced was clinically effective while expandng regulatory T cells and NK cells, which may benefit immune homeostasis in SLE patients.